Neuralink's N2 implant is a titanium coin the size of a shirt button, surgically placed in the skull with 1,024 electrodes that read and write neural signals. One hundred patients have now had it for at least six months. Here is what they say — including things Neuralink's PR team would rather you didn't hear.
The Medical Successes (Remarkable)
For patients with ALS, spinal cord injuries, and locked-in syndrome, the N2 results border on miraculous. The first patient — Noland Arbaugh, a quadriplegic — was widely reported in 2024. By 2026, the data from 100 patients tells a more complete and remarkable story:
- Average typing speed for paralyzed patients: 92 words per minute via neural typing (vs 0 before implant)
- Three patients regained partial motor control in upper limbs through motor cortex stimulation
- Visual prosthetics pilot: 2 patients with blindness reported light perception via visual cortex stimulation
- Average quality of life improvement: 7.8/10 as reported by patients and caregivers
The Complications (Not Hidden, But Underreported)
Neuralink's FDA filings reveal complications that media coverage has largely glossed over: 18% of patients experienced thread retraction (electrodes pulling back from tissue) requiring recalibration. 4 patients required explantation due to infection or device failure. Long-term biocompatibility data beyond 18 months is still limited.
"The medical case for Neuralink is strong and getting stronger. The ethical case for healthy enhancement implants is much more complicated." — Bioethics Journal, January 2026
Healthy Enhancement: The Controversial Frontier
Neuralink's roadmap includes "enhancement" implants for healthy individuals — improved memory, faster information processing, direct AI interface. A waitlist of 50,000 healthy people have expressed interest. Regulatory bodies in the US and EU have been clear: enhancement indications require a completely separate and far more rigorous approval pathway than medical necessity. That pathway will take years.
What's Next: N3 and Beyond
The N3, currently in preclinical trials, features 4,096 electrodes (4x the N2), bidirectional communication (reading and writing neural signals simultaneously), wireless charging, and 10-year device lifetime. If trials proceed on schedule, N3 will enter human trials in late 2027. The trajectory is clear — the question is how society decides to govern it.